APNEA (N6-[2-(4-Aminophenyl)ethyl]adenosine)
(Synonyms: 2-(4-氨基苯基)乙基腺苷-5'-羧酸,N6-[2-(4-Aminophenyl)ethyl]adenosine) 目录号 : GC33702
APNEA (N6-[2-(4-Aminophenyl)ethyl]adenosine) (N6-[2-(4-Aminophenyl)ethyl]adenosine) 是一种有效的、非选择性的 A3 腺苷受体激动剂。
![APNEA (N6-[2-(4-Aminophenyl)ethyl]adenosine) Chemical Structure](/media/struct/GC3/GC33702.png "APNEA (N6-[2-(4-Aminophenyl)ethyl]adenosine) Chemical Structure")
Cas No.:89705-21-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
APNEA is a potent, non-selective A3 adenosine receptor agonist.
APNEA is a non-selective agonist of the adenosine A3 receptors, at the subprotective dose of 1 mg/kg against electroconvulsions, significantly potentiates the anticonvulsive action of phenobarbital, diphenylhydantoin and valproate against maximal electroshock, being ineffective at lower doses. APNEA (0.0039-1 mg/kg) also enhances the protective activity of carbamazepine. APNEA at low doses potentiates the protective activity of Carbamazepine most likely through the A subtype of adenosine receptors. At higher doses, APNEA seems to enhance the anticonvulsive effect of other antiepileptics via adenosine A1 receptors[1].
APNEA (2-4 mg/kg) has no significant effect on seizure parameters (seizure severity, seizure duration and afterdischarge duration) in amygdala-kindled rats. N6-[2-(4-Aminophenyl)ethyl]adenosine is combined with antiepileptic drugs administered at doses ineffective in fully kindled rats[1].
[1]. Borowicz KK, et al. N6-2-(4-aminophenyl)ethyl-adenosine enhances the anticonvulsive activity of antiepileptic drugs. Eur J Pharmacol. 1997 May 30;327(2-3):125-133. [2]. Borowicz KK, et al. N(6)-2-(4-aminophenyl)ethyl-adenosine enhances the anticonvulsive action of conventional antiepileptic drugs in the kindling model of epilepsy in rats. Eur Neuropsychopharmacol. 2000 Jul;10(4):237-243.
| Cas No. | 89705-21-5 | SDF | |
| 别名 | 2-(4-氨基苯基)乙基腺苷-5'-羧酸,N6-[2-(4-Aminophenyl)ethyl]adenosine | ||
| Canonical SMILES | OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3NCCC4=CC=C(N)C=C4)O1)O)O | ||
| 分子式 | C18H22N6O4 | 分子量 | 386.41 |
| 溶解度 | DMSO : 50 mg/mL (129.40 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5879 mL | 12.9396 mL | 25.8792 mL |
| 5 mM | 0.5176 mL | 2.5879 mL | 5.1758 mL |
| 10 mM | 0.2588 mL | 1.294 mL | 2.5879 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet